최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0774540 (2010-05-05) |
등록번호 | US-9554993 (2017-01-31) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 413 |
A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, b
A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the medicament comprises forming a liquid feedstock, and forming a feedstock suspension by suspending in the liquid feedstock, the active agent and an excipient capable of forming a structural matrix, such as a phospholipid. The feedstock suspension is spray dried to produce the particulates.
1. An inhaleable powder composition comprising a plurality of particulate microstructures, the particulate microstructures comprising: (a) a structural matrix comprising phospholipid, wherein the particulate microstructures comprise greater than 10% phospholipid;(b) an active agent, wherein the part
1. An inhaleable powder composition comprising a plurality of particulate microstructures, the particulate microstructures comprising: (a) a structural matrix comprising phospholipid, wherein the particulate microstructures comprise greater than 10% phospholipid;(b) an active agent, wherein the particulate microstructures comprise greater than 50% active agent and wherein the active agent comprises an antibiotic;(c) residual amounts of a blowing agent, wherein the blowing agent comprises a fluorinated compound having a boiling point greater than 80° C., and wherein the residual amounts are 5% w/w or less; and(d) a mean aerodynamic diameter of less than 5 microns and a mean geometric diameter of less than 5 microns. 2. The inhaleable powder composition of claim 1 wherein the particulate microstructure comprises 1% w/w or less of blowing agent. 3. The inhaleable powder composition of claim 1 wherein the particulate microstructure comprises 3% w/w or less of blowing agent. 4. The inhaleable powder composition of claim 1 wherein the blowing agent comprises perfluorooctylbromide. 5. The inhaleable powder composition of claim 1 wherein the microstructures comprise a bulk density of less than 0.5 g/cm3. 6. The inhaleable powder composition of claim 1 wherein the microstructures have a mean porosity of 0.5-80%. 7. The inhaleable powder composition of claim 1 wherein the phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof. 8. The inhaleable powder composition of claim 1 wherein the structural matrix further comprises calcium. 9. The inhaleable powder composition of claim 1 wherein the powder has a fine particle fraction of from 30-70% by weight. 10. The inhaleable powder composition of claim 7 wherein the structural matrix further comprises calcium. 11. The inhaleable powder composition of claim 1 wherein the antibiotic comprises an aminoglycoside. 12. The inhaleable powder composition of claim 11 wherein the aminoglycoside comprises gentamicin. 13. The inhaleable powder composition of claim 1 wherein the blowing agent has a boiling point greater than 100° C. 14. An inhaleable powder composition comprising a plurality of particulate microstructures, the particulate microstructures comprising: (a) a structural matrix comprising phospholipid, wherein the particulate microstructures comprise greater than 10% phospholipid;(b) an active agent, wherein the particulate microstructures comprise greater than 50% active agent and wherein the active agent comprises an antibiotic;(c) residual amounts of a blowing agent, wherein the blowing agent comprises a fluorinated compound having a boiling point greater than 80° C., and wherein the residual amounts are 5% w/w or less;(d) residual amounts of a moisture, wherein the residual amounts are less than 6% w/w and wherein the moisture comprises water; and(e) a mean aerodynamic diameter of less than 5 microns. 15. The inhaleable powder composition of claim 14 wherein the residual amount of moisture is less than 3% w/w. 16. The inhaleable powder composition of claim 14 wherein the blowing agent has a boiling point greater than 100° C. and a mean geometric diameter of less than 5 microns. 17. The inhaleable powder composition of claim 14 wherein the phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof. 18. The inhaleable powder composition of claim 14 wherein the antibiotic comprises an aminoglycoside.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.